ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) lost -1.69 Percent and closed its previous trading session at $0.29. The stock traded with the average Volume of 2.45 Million at the end of last session.
ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) has the Market Capitalization of 6.74 Million. The Stock has its 52-week High of $4.270 and 52-Week Low of $0.030 and it touched its 52-week high on 01/10/17 and 52-Week Low on 08/11/17.
The company reported its last earnings Actual EPS of $-0.4/share. While, the analyst predicted that the company could provide an EPS of $-0.61/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.21/share which shows an Earnings Surprise of 34.4 Percent.
Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -11.53% where SMA50 and SMA200 are -20.05% and -74.71% respectively.
The company shows its Return on Assets (ROA) value of -224.5%.
ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) currently has a Weekly Volatility of 10.34% percent while its Monthly Volatility is at 8.71% percent. While talking about Performance of the Stock, ImmunoCellular Therapeutics, Ltd. currently has a Weekly performance of -12.55%, monthly performance percentage is -18.68 percent, Quarterly performance is 4.59 percent, 6 months performance shows a percent value of -73.36% and Yearly Performance is -90 percent.
ImmunoCellular Therapeutics, Ltd. operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular Therapeutics, Ltd. is based in California, USA.